Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
10
2022
accepted:
21
02
2023
medline:
4
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
epublish
Résumé
Although some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial. The PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model. Twenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I2 = 0%, P < .001; TBI: MD -4.82, 95%CI -8.06 to -1.58, I2 = 0%, P = .004). For subarachnoid hemorrhage (SAH) patients, it significantly decreased the risk of hydrocephalus (OR 1.23, 95%CI 1.01 to 1.50, I2 = 0%, P = .04) and rebleeding (OR, 0.52, 95%CI 0.35 to 0.79, I2 = 56% P = .002). There was no significance in modified Rankin Scale, Glasgow Outcome Scale 3-5, mortality, deep vein thrombosis, pulmonary embolism, or ischemic stroke/transient ischemic. Tranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.
Sections du résumé
BACKGROUND
Although some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial.
METHOD
The PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model.
RESULTS
Twenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I2 = 0%, P < .001; TBI: MD -4.82, 95%CI -8.06 to -1.58, I2 = 0%, P = .004). For subarachnoid hemorrhage (SAH) patients, it significantly decreased the risk of hydrocephalus (OR 1.23, 95%CI 1.01 to 1.50, I2 = 0%, P = .04) and rebleeding (OR, 0.52, 95%CI 0.35 to 0.79, I2 = 56% P = .002). There was no significance in modified Rankin Scale, Glasgow Outcome Scale 3-5, mortality, deep vein thrombosis, pulmonary embolism, or ischemic stroke/transient ischemic.
CONCLUSION
Tranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.
Identifiants
pubmed: 37000863
doi: 10.1371/journal.pone.0282726
pii: PONE-D-22-28422
pmc: PMC10065302
doi:
Substances chimiques
Antifibrinolytic Agents
0
Tranexamic Acid
6T84R30KC1
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282726Informations de copyright
Copyright: © 2023 Xiong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Sep 8;324(10):961-974
pubmed: 32897344
Neurosurgery. 1981 Feb;8(2):158-65
pubmed: 7010203
Crit Care. 2019 Jun 6;23(1):206
pubmed: 31171018
World Neurosurg. 2018 Jan;109:e748-e753
pubmed: 29074420
Postgrad Med J. 1971 Apr;47(546):199-200
pubmed: 5576488
Stroke Vasc Neurol. 2022 Apr;7(2):158-165
pubmed: 34848566
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Eur Stroke J. 2022 Sep;7(3):V
pubmed: 36082246
Stroke. 2017 Oct;48(10):2885-2887
pubmed: 28887388
Stroke Vasc Neurol. 2021 Jun;6(2):160-169
pubmed: 33795488
Curr Neurol Neurosci Rep. 2017 Sep 8;17(10):80
pubmed: 28887767
Malays J Med Sci. 2015 Dec;22(Spec Issue):62-71
pubmed: 27006639
CNS Drugs. 2019 Apr;33(4):327-336
pubmed: 30741383
Drugs. 2012 Mar 26;72(5):585-617
pubmed: 22397329
Front Pharmacol. 2019 Sep 19;10:1079
pubmed: 31607923
Curr Probl Cardiol. 2022 Nov;47(11):101328
pubmed: 35870549
N Engl J Med. 1984 Aug 16;311(7):432-7
pubmed: 6379455
JBJS Rev. 2015 Jun 2;3(6):
pubmed: 27490016
Health Technol Assess. 2012;16(13):iii-xii, 1-54
pubmed: 22417901
Rev Recent Clin Trials. 2020;15(1):70-75
pubmed: 31744452
Aesthetic Plast Surg. 2022 Feb;46(1):258-264
pubmed: 34351508
Lancet Neurol. 2020 Dec;19(12):980-987
pubmed: 33128912
J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1312-8
pubmed: 24680087
Acta Neurochir (Wien). 1990;102(1-2):1-10
pubmed: 2407050
BMC Emerg Med. 2013 Nov 22;13:20
pubmed: 24267513
Am J Emerg Med. 2021 Dec;50:748-752
pubmed: 34879498
Lancet. 2021 Jan 9;397(10269):112-118
pubmed: 33357465
Stroke. 1979 Sep-Oct;10(5):519-22
pubmed: 505491
JAMA Neurol. 2022 May 1;79(5):468-477
pubmed: 35311937
N Engl J Med. 2017 Jan 12;376(2):136-148
pubmed: 27774838
Anaesthesia. 2015 Jan;70 Suppl 1:50-3, e18
pubmed: 25440395
Can J Anaesth. 2021 Jun;68(6):894-917
pubmed: 33993459
Front Neurosci. 2021 Aug 30;15:677744
pubmed: 34526875
Br Med J. 1978 Apr 15;1(6118):945-7
pubmed: 346153
Int J Stroke. 2014 Oct;9(7):840-55
pubmed: 25156220
N Engl J Med. 2021 Apr 29;384(17):1623-1634
pubmed: 33913639
Lancet. 2019 Nov 9;394(10210):1713-1723
pubmed: 31623894
Rev Recent Clin Trials. 2019;14(4):286-291
pubmed: 31218964
Neurology. 2000 Jan 11;54(1):77-82
pubmed: 10636129
Ann Neurol. 1978 Jun;3(6):502-4
pubmed: 354483
Chin J Traumatol. 2017 Feb;20(1):49-51
pubmed: 28209450
Lancet. 2020 Jun 20;395(10241):1927-1936
pubmed: 32563378
J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105136
pubmed: 32912508
Stroke. 2021 Aug;52(8):2629-2636
pubmed: 34000834
J Am Heart Assoc. 2021 Feb;10(5):e019130
pubmed: 33586453
Turk Neurosurg. 2021;31(2):223-227
pubmed: 33624275
J Neurosurg. 2002 Oct;97(4):771-8
pubmed: 12405362
Clin Neurol Neurosurg. 2017 Feb;153:20-26
pubmed: 28006728
Lancet. 2018 May 26;391(10135):2107-2115
pubmed: 29778325
Eur J Trauma Emerg Surg. 2019 Aug;45(4):719-726
pubmed: 29922895